PH 804-Adoptive Cell Transfer T cell therapy(Phio pharmaceuticals)

N/A

Report date: 2022/08/26 15:43:00

Base Information

Drug NamePH 804-Adoptive Cell Transfer T cell therapy(Phio pharmaceuticals)

Drug Alias NameRXI-804-ACTPH-804-ACT

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityT cell immunoglobulin and ITIM domains inhibitors

TargetsT cell immunoglobulin and ITIM domains

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPhio Pharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesPhio Pharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A